Shennuo Medical Secures Nearly RMB 100 Million Series B Funding to Advance Breakthrough Neuromodulation Devices

VCBeat (WeChat: vcbeat) learned第一时间 that recently, SNEURO MEDICAL, an innovative company in the field of neuromodulation in China, has successfully completed a nearly 100-million-yuan B round of financing.

This round of financingLed by SDIC Chuanghe, with existing shareholder BioTrack Capital continuing to increase investment. The financing will be used for new product development, clinical research, registration applications, and chip iteration, among other areas.。In the past year, SNEURO MEDICAL has completed three rounds of financing exceeding 100 million yuan. The continuous recognition from professional investment institutions not only demonstrates the enormous potential of the neuromodulation sector but also validates the value of SNEURO MEDICAL's team and solutions.

Founded in 2018, SNEURO MEDICAL focuses on the independent research, development, and production of implantable medical devices in the field of neuromodulation. Committed to continuously providing doctors and patients with more advanced and effective treatment options, the company aims to improve the quality of life for more patients with difficult-to-treat conditions.

It is reported that SNEURO MEDICAL is developing neuromodulation products with different technical approaches and application scenarios, and all directions are proceeding smoothly. Meanwhile, SNEURO MEDICAL's next-generation product will use a self-developed chip.

The SNEURO MEDICAL team is composed of engineers with extensive experience in the research and development of implantable medical devices in the field of neurostimulation, several overseas-returning doctors specializing in chips and radio frequency, renowned American pain medicine experts, pain department experts from well-known hospitals, and various other professionals.With over a decade of comprehensive experience in the implantable medical device field, the SNEURO MEDICAL team has demonstrated outstanding capabilities in research and development of neuromodulation products, product system construction, and management.

ThroughThe core technologies such as electrodes, chips, wireless charging, algorithms, positioning and fixation, cloud management, and big data have been mastered to independently build a neuromodulation platform and advance the development of neuromodulation products.As of now, more than 60 related patents and software copyrights have been applied for, with 37 patents and software copyrights already authorized, including 4 invention patents.

Among them, the Spinal Cord Stimulator (SCS) is one of the company's core products.This product effectively treats intractable pain and achieves analgesic effects by implanting electrodes into the patient's spine to stimulate the spinal cord nerves with pulse currents, blocking pain signals from being transmitted through the spinal cord to the brain.

Peripheral Nerve Stimulation (PNS) is a temporary, short-term peripheral nerve modulation system independently developed by SNEURO MEDICAL to alleviate acute and chronic pain.This form of physical therapy has no drug side effects and fills the gap between opioid medications and expensive surgical neuromodulation.

In the future, SNEURO MEDICAL will continue to expand its product lines targeting conditions such as pain, urinary incontinence, heart failure, hypertension, and sleep apnea, achieving solution coverage across various fully implantable peripheral nerve stimulators and autonomic nerve stimulators. By establishing a complete line of neuromodulation products, it aims to further improve patients' quality of life while advancing the development of the neuromodulation industry.

SNEURO MEDICAL founder Wang Shou Dong said"Many thanks to SDIC Chuanghe, as well as existing shareholders CICC Chuanhe Fund and BioTrack Capital for their support and recognition of SNEURO MEDICAL. In the future, with the aggravation of aging in China, the demand for neuromodulation will become increasingly strong. We will use neuromodulation as a method to treat intractable neurological diseases in a less invasive form. Additionally, we will continue to focus on product line layout in the field of neuromodulation."

SDIC Chuanghe Biomedical Team Stated"We are optimistic about the application potential of neuromodulation technology in fields such as neuropathic pain, OAB, and heart failure. The SNEURO MEDICAL team has rich experience in neuromodulation research and development along with strong execution capabilities, continuously advancing innovative neuromodulation products and technologies. SDIC Chuanghe (Hangzhou) Venture Capital Management Co., Ltd. will make full use of industrial ecosystem resources to support SNEURO MEDICAL in its ongoing independent innovation, establishing a leading and comprehensive neuromodulation product portfolio to provide patients with more effective treatment options."

BioTrack Capital Investment Vice President Anan Wu stated"Neuromodulation is a track with tremendous potential and room for growth. As an emerging domestic enterprise, the company has its own technical characteristics and strategies. In this round of financing, we, as existing shareholders, continue to increase our investment, and remain optimistic about the future growth prospects of SNEURO MEDICAL."

SDIC Chuanghe is a professional guidance fund and industry fund management institution under the SDIC Group. It currently manages two national-level funds, two central government special funds, four regional industry funds, and three market-oriented funds, with directly managed assets exceeding 40 billion yuan. It focuses on equity investment, venture capital, and fund investment in strategic emerging industries. Under the advocacy of the National Development and Reform Commission, SDIC Chuanghe took the lead in establishing China's innovative biomedicine, artificial intelligence, new materials, and network information security venture capital service alliances. As a council member of the Asset Management Association of China, it continuously improves the investment ecosystem, unites public innovation efforts, and promotes the development of emerging industries.

BioTrack Capital was founded in 2017 as a professional investment institution focused on investing in and incubating outstanding healthcare startups in the Chinese market. We are not only investors but also long-term partners of entrepreneurs. We consistently support the most exceptional healthcare innovators, fostering the next generation of leading enterprises in China's healthcare industry.